BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 33860836)

  • 1. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
    Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
    Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
    [No Abstract]   [Full Text] [Related]  

  • 4. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
    Xu M; Casio M; Range DE; Sosa JA; Counter CM
    Clin Cancer Res; 2018 Sep; 24(17):4271-4281. PubMed ID: 30065097
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
    Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
    Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
    Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
    [No Abstract]   [Full Text] [Related]  

  • 9. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing FOXP2 reverses vemurafenib resistance in BRAF
    Jiang S; Huang Y; Li Y; Gu Q; Jiang C; Tao X; Sun J
    Endocrine; 2023 Jan; 79(1):86-97. PubMed ID: 36331719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary thyroid cancer organoids harboring BRAF
    Chen D; Su X; Zhu L; Jia H; Han B; Chen H; Liang Q; Hu C; Yang H; Liu L; Li P; Wei W; Zhao Y
    J Transl Med; 2023 Jan; 21(1):9. PubMed ID: 36624452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.
    Hu L; Zhang J; Tian M; Kang N; Xu G; Zhi J; Ruan X; Hou X; Zhang W; Yi J; Ma W; Chang L; Tang T; Zheng X; Wei X; Gao M
    Cell Death Dis; 2022 Feb; 13(2):124. PubMed ID: 35136031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition
    Chen LL; Gao GX; Shen FX; Chen X; Gong XH; Wu WJ
    Mol Cells; 2018 Sep; 41(9):853-867. PubMed ID: 30165731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
    Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
    J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in
    Zou M; Al-Yahya S; Al-Alwan M; BinEssa HA; Khabar KSA; Almohanna F; Assiri AM; Altaweel A; Qattan A; Meyer BF; Alzahrani AS; Shi Y
    Front Immunol; 2023; 14():1171816. PubMed ID: 37483610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.
    Tran KB; Kolekar S; Wang Q; Shih JH; Buchanan CM; Deva S; Shepherd PR
    Mol Cancer Ther; 2022 Dec; 21(12):1777-1787. PubMed ID: 36198029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF
    Zhang P; Guan L; Sun W; Zhang Y; Du Y; Yuan S; Cao X; Yu Z; Jia Q; Zheng X; Meng Z; Li X; Zhao L
    Clin Transl Med; 2024 May; 14(5):e1694. PubMed ID: 38797942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
    Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.